Multiplex PCR assays market seen topping $3.17 billion by 2030

The global multiplex PCR assays market is projected to grow from $1.7 billion in 2025 to $1.93 billion in 2026, then reach $3.17 billion by 2030, as demand rises for faster and more comprehensive diagnostic testing. North America led the market in 2025, while report publisher The Business Research Company is highlighting growth opportunities tied to infectious disease testing, personalized medicine and high-throughput platforms.

Why it matters: - Multiplex PCR assays are becoming a bigger part of molecular diagnostics as healthcare systems push for faster testing, earlier disease detection and more personalized treatment. - The market’s projected growth points to rising demand for multi-target tests that can improve efficiency and reduce the need for separate singleplex assays. - The market report frames the segment as a strategic opportunity across diagnostics, laboratory infrastructure and high-throughput testing.

What happened: - The Business Research Company released its Multiplex PCR Assays Global Market Report 2026 covering market size, trends and forecasts through 2035. - The report says the multiplex PCR assays market will rise from $1.7 billion in 2025 to $1.93 billion in 2026. - The report projects the market will reach $3.17 billion by 2030. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics, and updated graphics and tables. - A free sample is available here. - The full report is available here.

The details: - Multiplex PCR assays use polymerase chain reaction to simultaneously amplify and detect multiple DNA or RNA targets in a single test. - The method can test several genetic markers or pathogens from one sample. - The report says the market’s recent growth has been supported by rising infectious disease prevalence, wider use of molecular diagnostics, limits of singleplex PCR tests, demand for rapid results and growth in diagnostic laboratory infrastructure. - The report says future growth will be driven by early disease detection, demand for more comprehensive diagnostics, personalized medicine, higher investment in molecular diagnostics and broader routine use of multiplex assays. - The report expects growth in infectious disease panels, high-throughput diagnostic platforms, syndromic testing panels, clinical diagnostics and cost-efficient multi-target assays. - The report says growing diagnostic demand is tied to chronic diseases such as cancer and diabetes, along with preventive healthcare programs that encourage regular testing. - The NHS reported in July 2024 that U.K. diagnostic activity exceeded pre-pandemic levels in 2023, with tests up 21% in May 2024 versus a year earlier and 2.4 million diagnostic tests performed that month.

Between the lines: - The market outlook suggests multiplex PCR is moving from a specialized lab tool to a more standard diagnostic approach. - The forecast implies healthcare buyers want tests that can do more in one run, especially as infectious disease and chronic disease burdens rise. - The emphasis on syndromic panels and high-throughput systems signals where vendors may compete next: speed, breadth and cost per result.

What's next: - The report expects continued adoption of multiplex PCR in clinical diagnostics and routine testing through 2030. - Vendors and labs are likely to focus on broader panel design, automation and lower-cost multi-target workflows as demand grows. - The report’s forecast period extends through 2035, suggesting more long-range opportunity beyond the 2030 market estimate.

The bottom line: - Multiplex PCR assays are positioned for sustained double-digit growth as diagnostics shift toward faster, broader and more efficient testing.